Guide · Updated August 2026

What Is Orforglipron (Foundayo)? Lilly’s Oral GLP-1 Pill

Orforglipron, sold as Foundayo, is Eli Lilly's once-daily oral GLP-1 pill. The FDA approved it on April 1, 2026, for chronic weight management, and it started shipping from LillyDirect five days later. Unlike the existing GLP-1 pill Rybelsus, Foundayo does not require fasting or a water restriction around the dose. Here is what it is, how the dosing works, what the trials actually showed, and what it costs. Checked against manufacturer and FDA-sourced reporting, August 2026.

Quick Facts

How Orforglipron Is Different From Other GLP-1s

Every other GLP-1 medication on the market, including Ozempic, Wegovy, Mounjaro, and Zepbound, is a peptide. Peptides get broken down by stomach acid, which is why the injectable versions are injections in the first place, and why the one existing oral peptide GLP-1, Rybelsus (oral semaglutide), has to be taken first thing in the morning on an empty stomach with no more than 4 ounces of water, followed by a 30-minute wait before eating or taking other medication.

Orforglipron is not a peptide. It is a small molecule, chemically closer to an everyday pill than to insulin or semaglutide, and it absorbs through the gut without needing a special empty-stomach window. That is the entire pitch: GLP-1 receptor activation without an injection and without the timing rules that make Rybelsus inconvenient for a lot of people. Our oral vs. injectable GLP-1 guide compares Foundayo against Rybelsus and the higher-dose oral Wegovy pill in more detail.

Lilly also used the FDA’s National Priority Voucher program for this application, which is why Foundayo cleared review on April 1, ahead of its original April 10 target decision date.

I have been on injectable Mounjaro since 2024 and track my results with DEXA scans, so I get asked a lot whether a pill like this makes the injection obsolete. My honest read after going through the trial data: not yet, not at this efficacy gap. It is a real option for people who were never going to start an injectable in the first place, which is a large group, but it is not currently a like-for-like swap for someone already doing well on tirzepatide or semaglutide.

Dosing Schedule

Foundayo is titrated over six dose levels, and current prescribing guidance calls for holding each step for at least 30 days before increasing:

At the minimum pace, reaching the 17.2 mg maximum takes about five months. Not everyone needs to get there. As with the injectable GLP-1s, the prescribing information calls for using the lowest dose that produces an adequate response, not automatically climbing to the top.

One interaction detail worth knowing: for patients taking a strong CYP3A4 inhibitor (a category of drug interaction that also affects many other medications), the maximum recommended orforglipron dose is capped at 9 mg regardless of how the patient otherwise tolerates the medication. If you take other prescription medications, this is a question for your prescriber or pharmacist, not something to self-assess.

What the Trials Actually Showed

The headline number Lilly has publicized most is 12.4% weight loss (27.3 lbs) at 72 weeks in the ATTAIN-1 trial, a placebo-controlled Phase 3 study of 3,127 adults with obesity or overweight without diabetes. That figure describes the highest dose tested in the trial, an investigational capsule formulation Lilly has said is bioequivalent to the 17.2 mg tablet that reached the market.

The FDA label’s own efficacy table for the actual commercial tablet, drawn from the same trial, reports a slightly different number: 11.1% weight loss (25.2 lbs) at the 17.2 mg dose over 72 weeks, against 2.1% (4.8 lbs) for placebo. Lower doses showed a clear dose-response pattern in the same trial: roughly 8.3% (18.7 lbs) at 9 mg and 7.4% (16.8 lbs) at 5.5 mg. Both numbers come from real data. They reflect different formulations and reporting conventions inside the same trial program, not a change in what the drug actually does. Use the tablet-specific 11.1% figure if you want the number that maps to what actually ships in a bottle.

For comparison, injectable tirzepatide (Mounjaro/Zepbound) produced 20.9% weight loss at its top dose in the SURMOUNT-1 trial, and injectable semaglutide (Wegovy) produced about 14.9%. Orforglipron’s results are meaningful but currently trail both injectables. A pill with somewhat lower average weight loss is still the right trade-off for some people, particularly anyone who was avoiding GLP-1 treatment specifically because of needle aversion or the Rybelsus food and water rules.

Side Effects and the Boxed Warning

Foundayo carries the same class-wide boxed warning as every other approved GLP-1: a warning about thyroid C-cell tumors, based on findings in rodent studies of medicines that work the same way, not on evidence of the effect in humans. Notably, orforglipron itself did not produce these tumors in the rodent testing Lilly conducted, and it is not known whether the class warning applies to humans at all for any GLP-1. It is required on the label as a precaution. Anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not take it, and anyone who develops a neck lump, persistent hoarseness, trouble swallowing, or shortness of breath while on it should contact their prescriber.

Gastrointestinal side effects are common and were the most frequent reason people stopped treatment in ATTAIN-1:

• Nausea: reported in roughly 29% to 36% of participants depending on dose, generally described as mild to moderate and most likely to occur when starting or increasing the dose
• Diarrhea, vomiting, and constipation: also common, following the same starting-dose and dose-increase pattern
• Discontinuation due to side effects: ranged from about 5% to 10% depending on dose, with GI symptoms specifically driving discontinuation in roughly 3% to 6% of participants, compared with under 1% on placebo

Reported GI rates for orforglipron run on the higher end compared with other GLP-1s, though direct comparisons across different trials are unreliable since each drug’s studies used different populations and protocols. The GI side effect pattern (worse when starting or increasing dose, easing over time) matches what people report on injectable tirzepatide and semaglutide.

Price and Where to Get It

Lilly priced Foundayo by dose tier for the LillyDirect self-pay channel, so cost increases as the dose increases rather than staying flat through titration:

These are the tiers Lilly announced at the April 2026 launch. For patients with eligible commercial insurance who use Lilly’s savings card, the price can drop to as little as $25 per month, similar to the structure Lilly uses for the Zepbound and Mounjaro savings cards covered in our copay card guide. Foundayo launched through LillyDirect and is expanding into retail pharmacy channels, including Amazon Pharmacy and GoodRx pricing lookups, so availability outside the direct-to-consumer channel should keep widening through 2026. As with any manufacturer program, confirm current pricing on LillyDirect before ordering rather than relying on the launch figures above.

Is It Approved for Type 2 Diabetes?

Not yet, as of this writing. The current approval covers weight management only. Lilly’s separate Phase 3 ACHIEVE trial program is testing orforglipron for type 2 diabetes, and several of those trials, including a head-to-head against oral semaglutide (Rybelsus), reported results at the 2026 American Diabetes Association Scientific Sessions. In a 72-week diabetes trial, orforglipron produced meaningful A1C reductions alongside weight loss around 5% to 10% depending on dose, more than the roughly 2.5% seen with placebo. Lilly has said it plans to file a separate FDA application for the diabetes indication later in 2026. Until that application is approved, prescribing orforglipron specifically for diabetes management would be off-label.

FAQ

Is Foundayo the same as Ozempic or Wegovy?

No. They are all GLP-1 receptor agonists, but Ozempic and Wegovy contain semaglutide, a peptide. Foundayo contains orforglipron, a non-peptide small molecule. They work on the same receptor but are chemically different drugs with different dosing, different side effect rates, and different trial results.

Does Foundayo need to be taken on an empty stomach?

No. This is the main practical difference from Rybelsus (oral semaglutide), which must be taken first thing in the morning with minimal water and a 30-minute wait before eating. Foundayo can be taken at any time of day, with or without food or water.

How does Foundayo compare to Mounjaro or Zepbound for weight loss?

Injectable tirzepatide (Mounjaro/Zepbound) produced more weight loss in its own trials, 20.9% at the top dose in SURMOUNT-1 versus 11.1% for Foundayo’s top tablet dose in its own trial. Foundayo trades some efficacy for the convenience of a pill and no injection.

Is Foundayo covered by insurance?

Coverage varies by plan and is still developing since the drug is newly approved. Lilly’s savings card can bring the price to as little as $25 per month for people with eligible commercial insurance whose plan covers Foundayo. Check your specific formulary rather than assuming coverage either way.

Will there be an oral tirzepatide pill like Foundayo?

Not currently. Foundayo is built on orforglipron, a different molecule from tirzepatide (Mounjaro/Zepbound). Eli Lilly has not announced an oral tirzepatide product. If one is developed, it would be a separate drug application, not a repackaging of the injectable.

This guide summarizes publicly reported trial data, FDA approval information, and manufacturer pricing for general information only. It is not medical advice and does not recommend Foundayo or any other medication for any individual. Whether a GLP-1 medication is appropriate, and at what dose, is a decision between a patient and a licensed prescriber. Full details in our disclaimer.

Related

Guides:

• Oral vs Injectable GLP-1
• GLP-1 vs. Bariatric Surgery
• GLP-1 Copay Cards and Patient Assistance Programs
• Tirzepatide Dosage Chart: mg to Units

Medications: Mounjaro · Wegovy · Compounded Tirzepatide

Compare: All Providers · Best GLP-1 Programs · All Guides